【摘 要】
：
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who
【机 构】
：
Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medic
【出 处】
：
2013年中国肾性贫血治疗专家共识研讨会
论文部分内容阅读
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who were receiving adequate epoetin doses and who had ferritin levels between 500 and 1200 ng/ml and transferrin saturation (TSAT) ≤25%.The DRIVE-Ⅱ study reported here was a 6-wk observational extension designed to investigate how ferric gluconate impacted epoetin dosage after DRIVE.During DRIVE-Ⅱ, treating nephrologists and anemia managers adjusted doses of epoetin and intravenous iron as clinically indicated.By the end of observation, patients in the ferric gluconate group required significantly less epoetin than their DRIVE dose (mean change of-7527 ± 18,021 IU/wk, P =0.003), whereas the epoetin dose essentially did not change for patients in the control group (mean change of 649 ±19,987 IU/wk, P =0.809).Mean hemoglobin, TSAT, and serum ferritin levels remained higher in the ferric gluconate group than in the control group (P =0.062, P < 0.001, and P =0.014, respectively).Over the entire 12-wk study period (DRIVE plus DRIVE-Ⅱ), the control group experienced significantly more serious adverse events than the ferric gluconate group (incidence rate ratio =1.73, P =0.041).In conclusion, ferric gluconate maintains hemoglobin and allows lower epoetin doses in anemic hemodialysis patients with low TSAT and ferritin levels up to 1200 ng/ml.
其他文献
Background.Concomitant iron supplementation is required in the great majority of erythropoietin (Epo)-treated patients with end-stage renal failure.Intravenous (i.v.) iron supplementation has been dem
Background.Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients.However, the optimal
Iron deficiency limits the efficacy of recombinant human erythropoietin (rhEPO) therapy in end-stage renal disease (ESRD)patients.Functional iron deficiency occurs with serum ferritin >500 ng/ml and/o
Iron deficiency is an important cause of anemia in patients with chronic kidney disease (CKD), but intravenous iron is infrequently used among patients who are not on dialysis.Ferumoxytol is a novel i
Background: Serum ferritin, frequently used as a marker of iron status in individuals with chronic kidney disease, is also an inflammatory marker.The concurrent combination of high serum ferritin and
Background and objectives: As well as being a marker of body iron stores, serum ferritin (sFerritin) has also been shown to be a marker of inflammation in hemodialysis (HD) patients.The aim of this st
铁是合成血红蛋白的基本原料.流行病学及临床的研究证实在慢性肾脏病(CKD)贫血患者中常常存在一定程度的铁缺乏[1,2],铁缺乏也是导致红细胞刺激剂(ESA)治疗反应差的主要原因,予以充足的铁补充 ,不仅可以明显改善贫血,还可以减少ESA的使用剂量,甚至在未使用ESA的情况下也能改善贫血[3,4].因此对于CKD贫血患者需常规进行铁状态的评价,搜寻导致铁缺乏的原因.并根据患者的铁状态予以相应的铁剂补
Introduction Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree
Introduction Despite major recent therapeutic improvements, septic shock remains a leading cause of mortality in intensive care patients [1].For more than a decade, it has been advocated [2,3] that th
Sodium ferric gluconate complex in hemodialysis patients:Adverse reactions compared to placebo and iron dextran.Background.Parenteral iron is often required by hemodialysis patients to maintain adequa